TickerGuard
Buy Day today: Neutral (54) Mixed market breadth · no major macro event
NERV

Minerva Neurosciences Inc

Healthcare · Biotechnology

3.30$ +1.2% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Balance Sheet

Minerva Neurosciences Inc (NERV) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 95 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet NERV
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
142 133 135 127 194 184 174 161 151 139 130 120 111 77 69 66 65 58 112 105 98 77 71 65 60 55 52 67 63 56,900 51 46 43 37 33 30 28 98 94 95
93 84 86 78 134 130 125 112 101 90 80 71 61 47 38 36 35 27 82 75 67 62 56 50 45 40 37 52 48 42,002 36 31 28 22 18 16 13 83 79 80
92 83 69 50 36 26 45 69 87 50 31 28 38 21 30 32 33 25 80 74 66 61 55 50 40 36 36 52 47 40,913 35 31 27 21 17 15 12 82 33 25
92 83 85 78 133 128 121 108 98 88 79 69 60 46 38 35 33 25 80 74 66 61 55 50 40 36 36 52 47 40,913 35 31 27 21 17 15 12 82 78 75
– – – – – – – – – – – – – – – – – – – – – – – – 3.1 3.1 – – – – – – – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – -3.0 – – – – – – – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 – – – – – 0.0 0.0 0.0 – – – – – – – – – – – –
15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 14,869 15 15 15 15 15 15 15 15 15 15
34 34 34 34 34 34 34 34 34 34 34 34 34 15 15 15 15 15 15 15 15 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – –
29 27 29 29 63 52 53 50 49 49 52 53 55 50 50 9.2 7.2 5.0 66 69 69 69 71 73 74 75 78 80 83 85,357 87 91 64 63 62 63 63 239 348 297
10 9.7 13 15 8.7 6.8 7.9 5.0 3.9 3.6 6.9 7.6 9.9 6.6 7.1 7.4 5.4 3.2 3.4 4.4 3.1 2.8 3.2 3.4 2.2 1.4 2.5 1.9 3.3 3,340 2.8 4.2 4.5 2.8 1.9 2.5 2.7 2.3 4.5 4.0
4.8 4.9 5.0 5.1 5.2 4.0 2.7 1.4 41,176 41,176 0.7 1.1 1.6 0.2 0.2 0.2 0.2 0.1 0.1 0.0 – – – – – – – – – – – – – – – – – – – –
0.8 1.5 3.3 1.4 1.5 1.4 2.8 1.3 0.9 1.8 3.0 2.9 5.3 2.3 3.0 3.1 0.7 1.0 1.1 1.6 1.2 1.9 1.6 1.5 0.5 1.0 1.0 0.3 1.4 1,805 1.4 0.8 0.6 1.6 0.6 0.9 0.9 0.6 2.1 1.4
5.0 3.8 2.6 1.3 0.0 0.0 0.0 0.0 0.0 – 0.2 – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
113 106 106 98 130 132 121 111 101 90 77 67 56 28 19 57 58 53 45 36 28 8.0 -0.7 -8.4 -14 -20 -27 -13 -20 -28,457 -37 -44 -22 -26 -29 -32 -35 -141 -254 -202
-123 -133 -144 -153 -165 -164 -177 -189 -201 -215 -230 -243 -257 -287 -299 -269 -277 -285 -294 -304 -313 -335 -344 -353 -360 -367 -374 -380 -388 -396,815 -405 -414 -391 -395 -399 -402 -405 -689 -814 -797
4.4 4.4 4.4 4.6 5.1 4.8 4.8 4.8 4.8 4.9 4.9 4.9 4.9 4.9 4.9 5.0 5.2 5.2 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.5 7.6 6.5 7.6 7.6 7.6 7.6 7.6 7.6 7.6 11 44 79

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?